口服阿扎胞苷治疗首次缓解急性髓系白血病患者中NPM1和FLT3突变的预后影响
QUAZAR AML-001随机安慰剂对照3期试验评估口服阿扎胞苷(Oral-AZA)用于强化化疗后首次缓解且不适合造血干细胞移植的急性髓系白血病(AML)患者。按NPM1和FLT3突变状态分层分析显示,NPM1突变患者中Oral-AZA较安慰剂改善总生存(HR 0.63)和无复发生存(HR 0.55),FLT3突变患者中无复发生存改善(HR 0.51)而总生存未达统计学显著(HR 0.63,95%CI 0.35-1.12)。
要点
- NPM1突变患者中Oral-AZA较安慰剂改善OS(HR 0.63)和RFS(HR 0.55)。
- FLT3突变患者中Oral-AZA较安慰剂改善RFS(HR 0.51),OS差异未达统计学显著。
- 多因素分析中Oral-AZA的生存获益独立于NPM1/FLT3突变状态、细胞遗传学风险及MRD状态。
核心结论
- 在强化化疗后首次缓解的AML患者中,口服阿扎胞苷改善NPM1突变患者的OS和RFS,改善FLT3突变患者的RFS,其生存获益独立于NPM1或FLT3突变状态、细胞遗传学风险和化疗后MRD状态。
研究设计与样本
- 随机、安慰剂对照的3期QUAZAR AML-001试验(ClinicalTrials.gov标识符:NCT01757535)。
- 纳入强化化疗后首次缓解且不适合造血干细胞移植的AML患者,按1:1随机接受口服阿扎胞苷300 mg或安慰剂,每28天周期用药14天。
- 472例随机患者中469例(99.4%)有可用突变数据;137例(29.2%)有NPM1突变,66例(14.1%)有FLT3突变,30例(6.4%)诊断时同时有NPM1突变和FLT3-ITD。
- 诊断时基因突变来自病例报告表;MRD由多参数流式细胞术集中检测。
主要发现
- NPM1突变患者中,口服阿扎胞苷较安慰剂改善OS(HR 0.63;95%CI 0.41-0.98)和RFS(HR 0.55;95%CI 0.35-0.84)。
- NPM1突变且无MRD患者中,口服阿扎胞苷中位OS为48.6个月 vs 安慰剂31.4个月;NPM1突变且有MRD患者中为46.1个月 vs 10.0个月。
- FLT3突变患者中,口服阿扎胞苷较安慰剂改善RFS(HR 0.51;95%CI 0.27-0.95),OS差异未达统计学显著(HR 0.63;95%CI 0.35-1.12)。
- FLT3突变且无MRD患者中,口服阿扎胞苷中位OS为28.2个月 vs 安慰剂16.2个月;FLT3突变且有MRD患者中为24.0个月 vs 8.0个月。
- 多因素分析中,口服阿扎胞苷显著改善生存,独立于NPM1或FLT3突变状态、细胞遗传学风险或化疗后MRD状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial (ClinicalTrials.gov identifier: NCT01757535) evaluated oral azacitidine (Oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC) who were not candidates for hematopoietic stem cell transplantation. Eligible patients were randomized 1:1 to Oral-AZA 300 mg or placebo for 14 days per 28-day cycle. We evaluated relapse-free survival (RFS) and overall survival (OS) in patient subgroups defined by NPM1 and FLT3 mutational status at AML diagnosis and whether survival outcomes in these subgroups were influenced by presence of post-IC measurable residual disease (MRD). Gene mutations at diagnosis were collected from patient case report forms; MRD was determined centrally by multiparameter flow cytometry. Overall, 469 of 472 randomized patients (99.4%) had available mutational data; 137 patients (29.2%) had NPM1 mutations (NPM1mut), 66 patients (14.1%) had FLT3 mutations (FLT3mut; with internal tandem duplications [ITD], tyrosine kinase domain mutations [TKDmut], or both), and 30 patients (6.4%) had NPM1mut and FLT3-ITD at diagnosis. Among patients with NPM1mut, OS and RFS were improved with Oral-AZA by 37% (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.98) and 45% (HR, 0.55; 95% CI, 0.35-0.84), respectively, vs placebo. Median OS was improved numerically with Oral-AZA among patients with NPM1mut whether without MRD (48.6 months vs 31.4 months with placebo) or with MRD (46.1 months vs 10.0 months with placebo) post-IC. Among patients with FLT3mut, Oral-AZA improved OS and RFS by 37% (HR, 0.63; 95% CI, 0.35-1.12) and 49% (HR, 0.51; 95% CI, 0.27-0.95), respectively, vs placebo. Median OS with Oral-AZA vs placebo was 28.2 months vs 16.2 months, respectively, for patients with FLT3mut and without MRD and 24.0 months vs 8.0 months for patients with FLT3mut and MRD. In multivariate analyses, Oral-AZA significantly improved survival independent of NPM1 or FLT3 mutational status, cytogenetic risk, or post-IC MRD status.
引用
- Döhner H, Wei AH, Roboz GJ, et al. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022. PMID: 35960871. doi:10.1182/blood.2022016293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。